Skip to Main Content

Paper Details

Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.
Ann Clin Transl Neurol
20
2019
NF1, children, cognitive deficits, human, latent factors, lovastatin, neurodevelopmental disorders, neurofibromatosis type 1
Author NameAffiliation
Gary CutterSchool of Public Health, University of Alabama at Birmingham
Michael J FisherThe Children's Hospital of Philadelphia
David H GutmannWashington University School of Medicine
Roger J PackerCenter for Neuroscience and Behavioral Medicine
Roger J PackerCenter for Neuroscience and Behavioral Medicine
Maria T AcostaCenter for Neuroscience and Behavioral Medicine
Maria T AcostaNational Institutes of Health, National Human Genome Research Institute
Kathryn N NorthMurdoch Children's Research Institute, Royal Children's Hospital
Kathryn N NorthUniversity of Melbourne
  • 1 - 9

Datasets

Release 1.2